MUC1 antibody-drug conjugate

MUC1 antibody-drug conjugates (ADCs) are a class of targeted cancer therapeutics designed to deliver potent cytotoxic payloads directly to cells expressing Mucin-1 (MUC1). MUC1 is a transmembrane glycoprotein that is frequently overexpressed and aberrantly glycosylated in various epithelial cancers, including breast, lung, pancreatic, and ovarian malignancies. These ADCs typically consist of a monoclonal antibody targeting the extracellular domain of MUC1—often the SEA domain to avoid binding to shed, circulating forms—conjugated via a chemical linker to a cytotoxic agent such as a topoisomerase I inhibitor or a microtubule-disrupting agent. Upon binding to the MUC1 antigen on the tumor cell surface, the ADC is internalized through endocytosis, and the payload is released within the lysosomal compartment, leading to targeted cell death. This approach aims to enhance the therapeutic index of chemotherapy by concentrating the drug's activity within the tumor while minimizing systemic toxicity.

Other names

MUC1 antibody-drug conjugateMUC-1 antibody-drug conjugateMUC 1 antibody-drug conjugateMUC1 ADCMUC-1 ADCMUC 1 ADCMUC1-targeted ADCMUC-1-targeted ADCMUC 1-targeted ADCanti-MUC1 ADCanti-MUC-1 ADCanti-MUC 1 ADCMUC1-ADCMUC-1-ADCMUC 1-ADC